It is reported that GBP2 exerted anti-tumour effects by inhibiting the Wnt/β-catenin pathway in skin cutaneous melanoma (SKCM) (57) and showed an association with poor prognosis in SKCM when its expression decreased (58). This evidence concerns the gene GBP2 and neoplasm.